Literature DB >> 34372774

Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study.

Yuta Yoshimura1, Masahide Hamaguchi2, Yoshitaka Hashimoto1, Takuro Okamura1, Naoko Nakanishi1, Akihiro Obora3, Takao Kojima3, Michiaki Fukui1.   

Abstract

BACKGROUND: Hepatic steatosis has a pivotal role in the development of chronic liver diseases, even in alcohol-related liver disease. Alcoholic fatty liver disease is an important phenotype among alcohol-related liver diseases. While metabolic syndrome is a dominant risk factor of incident nonalcoholic fatty liver disease, the role of metabolic syndrome in alcoholic fatty liver disease has not been clarified yet.
METHODS: A retrospective cohort study was performed at a health check-up center in Japan. Subjects consisted of male participants without fatty liver who consumed ethanol of 420 g/week or higher. Adjusted hazard ratios and 95% confidence intervals at the baseline examinations for incident alcoholic fatty liver disease were estimated using Cox model.
RESULTS: A total of 640 participants were included in this study. During 3.91 years (IQR 1.63-7.09) of follow-up, 168 new cases of alcoholic fatty liver disease developed (49.1 cases per 1000 persons per year). After adjustment for age, smoking status, alcohol consumption, the hazard ratio for a 1 kg/m2 increase in body mass index was 1.2 (1.12-1.28). The hazard ratio of subjects with high triglyceride and low high-density lipoprotein-cholesterol levels were 1.56 (1.12-2.18) and 1.52 (1.03-2.25), respectively.
CONCLUSIONS: Obesity, high triglyceridemia, and low high-density lipoprotein-cholesterolemia are independent risk factors of alcoholic fatty liver disease in Japanese men who consumed alcohol habitually. In people with these risks, triglyceride lowering and high-density lipoprotein-cholesterol raising by improving insulin resistance and weight maintenance in addition to abstinence from alcohol would be effective in preventing the development of alcoholic fatty liver disease.
© 2021. The Author(s).

Entities:  

Keywords:  Alcohol-related liver disease; Dyslipidemia; Fatty liver; Metabolic syndrome; Obesity

Year:  2021        PMID: 34372774     DOI: 10.1186/s12876-021-01893-4

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  42 in total

Review 1.  Steatosis: co-factor in other liver diseases.

Authors:  Elizabeth E Powell; Julie R Jonsson; Andrew D Clouston
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

2.  Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.

Authors:  Nathalie Ganne-Carrié; Cendrine Chaffaut; Valérie Bourcier; Isabelle Archambeaud; Jean-Marc Perarnau; Frédéric Oberti; Dominique Roulot; Christophe Moreno; Alexandre Louvet; Thông Dao; Romain Moirand; Odile Goria; Eric Nguyen-Khac; Nicolas Carbonell; Térésa Antonini; Stanislas Pol; Victor de Ledinghen; Violaine Ozenne; Jean Henrion; Jean-Marie Péron; Albert Tran; Gabriel Perlemuter; Xavier Amiot; Jean-Pierre Zarski; Michel Beaugrand; Sylvie Chevret
Journal:  J Hepatol       Date:  2018-08-06       Impact factor: 25.083

Review 3.  Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study.

Authors:  Mark Thursz; Patrick S Kamath; Philippe Mathurin; Gyongyi Szabo; Vijay H Shah
Journal:  J Hepatol       Date:  2019-01-15       Impact factor: 25.083

Review 4.  Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma.

Authors:  Hamza Chettouh; Marie Lequoy; Laetitia Fartoux; Corinne Vigouroux; Christèle Desbois-Mouthon
Journal:  Liver Int       Date:  2015-07-23       Impact factor: 5.828

Review 5.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

6.  Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study.

Authors:  T Deleuran; H Grønbaek; H Vilstrup; P Jepsen
Journal:  Aliment Pharmacol Ther       Date:  2012-04-10       Impact factor: 8.171

7.  Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver.

Authors:  M R Teli; C P Day; A D Burt; M K Bennett; O F James
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

8.  Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis.

Authors:  T I Sørensen; M Orholm; K D Bentsen; G Høybye; K Eghøje; P Christoffersen
Journal:  Lancet       Date:  1984-08-04       Impact factor: 79.321

9.  Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Authors:  Kazuyuki Ohata; Keisuke Hamasaki; Kan Toriyama; Kojiro Matsumoto; Akira Saeki; Kenji Yanagi; Seigou Abiru; Yuichi Nakagawa; Masaya Shigeno; Seiji Miyazoe; Tatsuki Ichikawa; Hiroki Ishikawa; Kazuhiko Nakao; Katsumi Eguchi
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

Review 10.  Molecular pathways of nonalcoholic fatty liver disease development and progression.

Authors:  Fernando Bessone; María Valeria Razori; Marcelo G Roma
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.